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Signaling pathways elicited by protease-activated receptor-1 (PAR-1) agonists, thrombin receptor-activating peptide (TRAP) and
thrombin, are markedly different. Here we show that TRAP-induced disaggregation of platelets is a function of extracellular calcium.
Chelation of calcium with EGTA after the onset of aggregation precluded subsequent destabilization of the aggregates in TRAP-stimulated
platelets, whereas disaggregation was not observed in the platelets stimulated with thrombin. TRAP-induced disaggregation was independent
of the activity of the calcium-dependent thiol protease, calpain. Inhibition of phosphoinositide 3-kinase activity provoked further
destabilization of the platelet aggregates in the presence of calcium; however, EGTA attenuated this effect. Activation of protein kinase C
(PKC) by phorbol ester prevented disaggregation of the TRAP-stimulated platelets independent of the extracellular calcium. Two proteins of
relative mobilities 67 and 75 kD were found to be significantly dephosphorylated on tyrosine in calcium-pretreated platelets as compared to
the EGTA-treated platelets following continued stimulation with either TRAP or thrombin for 15 min. Inhibition of phosphoinositide 3-
kinase by two pharmacologically independent inhibitors also caused dephosphorylation of p67, which was completely abrogated by chelation
of extracellular calcium. Platelet activation by phorbol ester was not associated with disaggregation, although dephosphorylation of p67 was
induced under this condition. SHP-1, an abundant tyrosine phosphatase in platelets, co-migrated with the p67 protein and co-localized to the
actin-based cytoskeleton of aggregated platelets; however, its identity with p67 was ruled out from immunoprecipitation studies.
D 2004 Elsevier B.V. All rights reserved.Keywords: Platelet; Protease-activated receptor-1; Thrombin receptor-activating peptide; Protein tyrosine phosphatase; Protein tyrosine kinase1. Introduction
Calcium plays a pivotal role in several platelet functions
[1]. Rise in intracellular calcium in activated platelets is due0167-4889/$ - see front matter D 2004 Elsevier B.V. All rights reserved.
doi:10.1016/j.bbamcr.2004.06.006
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12-myristate 13-acetate; PAO, phenylarsine oxide; DMSO, dimethylsulf-
oxide; TBS, tris-buffered saline; PI 3-kinase, phosphoinositide 3-kinase;
PKC, protein kinase C; ICY, integrin cytoplasmic tyrosine
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more intracellular pools. In nonexcitable cells such as
platelets, influx of extracellular calcium is thought to be
controlled by agonists acting directly on plasma membrane
calcium channels as well as by the level of intracellular
calcium stores, which together result in a very rapid
transient of cytosolic calcium followed by decrease to a
steady-state bcalcium plateauQ [2]. The entry of extracellular
calcium takes place through two different calcium channels
in the early and late phases of agonist stimulation,
respectively [3]. Both direct and indirect coupling mecha-
nisms account for the calcium entry that results from
intracellular store depletion. Indirect coupling assumes the
existence of diffusible messengers such as cGMP [4],ta 1693 (2004) 147–157
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The direct coupling model has received support from studies
indicating that the mechanism of activation of store-
mediated calcium entry (SMCE) shares properties with the
activation of secretion [7]. The reorganization of the actin
cytoskeleton appears to play a critical role in the activation
of SMCE, possibly mediating coupling of the Ca2+ stores to
the plasma membrane [8,9].
Human platelets express several protease-activated
receptors (PARs), which include PAR-1 [10], -3 [11,12]
and -4 [13,14], whereas PAR-2 has been described in the
rodent platelets as well as in human endothelial cells [13].
Current evidence suggests that PAR-1 and PAR-4 are the
major human platelet thrombin receptors. Specific agonist
peptides have been designed for the thrombin-independent
activation of PAR1 and PAR4. Thrombin activates platelets
by hydrolyzing PAR-1, thereby exposing a new N-terminal
sequence, a tethered ligand, which initiates a cascade of
molecular reactions leading to thrombus formation. Throm-
bin receptor-activating peptide (TRAP, SFLLRN) corre-
sponds to the amino terminus of the cleaved thrombin
receptor PAR-1 [15]. PAR-4 in human platelets is activated
by higher dose of thrombin, cleaving its N-terminal
exodomain at the R47/G48 peptide bond to unmask the
tethered ligand GYPGQV. The synthetic peptide GYPGQV
functions as an agonist for PAR-4 at higher concentrations
(200–500 AM) [14,16].
Platelet adhesion and aggregation are relatively early
events following activation of the platelets. Signaling
reactions associated with this early phase had been the
focus of intense research in the past. In an in vivo setup,
however, platelets continue to be exposed to the agonists
long after the clot is formed, which is responsible for
physiological responses like clot retraction [17], micro-
vesicle shedding [18–20] and pro-apoptotic changes [21].
We have recently pointed to significant differences in the
regulation of postligand binding signaling pathways evoked
by prolonged exposure to the PAR-1 agonists, thrombin or
TRAP [22]. TRAP, in the presence of extracellular calcium,
induces disaggregation of platelets while thrombin does not.
In this report we have studied regulation of signaling
pathways induced by sustained ligation of thrombin
receptors with either TRAP or thrombin.2. Materials and methods
2.1. Reagents
Polyclonal antibody against SHP-1 (sc-287), monoclonal
antibodies against phosphotyrosine (clone PY99) and horse-
radish peroxidase-labeled secondary antibodies were pur-
chased from Santa Cruz (Santa Cruz, CA). The mAb clone
PY20 against phosphotyrosine was from Transduction Lab,
Lexington, KY. The anti-integrin aIIbh3 rabbit polyclonal
antibody, anti-Src mAb (MAP 327) and abciximab werekind gifts from Dr. Michael Berndt (Baker Institute,
Melbourne), Dr. Peter Presek (Martin-Luther-Universt7t,
Halle-Wittenberg) and Dr. Robert E. Jordan (Centocor,
Pennsylvania), respectively. The Super Signal West Pico
chemiluminescent substrate was from Pierce (Rockford, IL).
Human thrombin, TRAP (SFLLRNPNDKYEPF), PMA,
wortmannin, apyrase, EGTA, sodium orthovanadate, ace-
tylsalicylic acid, bovine serum albumin (BSA) fraction V,
Triton X-100, leupeptin, pepstatin A, aprotinin, phenyl-
methylsulfonyl fluoride, phenylarsine oxide (PAO), dime-
thylsulfoxide (DMSO), HEPES and protein A immobilized
on sepharose CL-4B were the products of Sigma (St. Louis,
MO). Tween-20 was from Bio-Rad (Richmond, CA).
Calpeptin and LY 294002 were from Biomol (Plymouth
Meeting, PA). The reagents for electrophoresis were
procured from Sisco Research Laboratory and Spectrochem,
India. All other reagents were of analytical grade.
2.2. Platelet preparation
Blood from volunteers was collected in citrate–phos-
phate–dextrose and centrifuged at 180g for 20 min.
Platelet-rich plasma was incubated with 1 mM acetylsali-
cylic acid and 0.15 ADPase units of apyrase/ml for 15 min
at 37 8C. After addition of EDTA (5 mM), platelets were
sedimented by centrifugation at 800g for 15 min. The
cells were resuspended in buffer A (20 mM HEPES, 138
mM NaCl, 2.9 mM KCl, 1 mM MgCl2, 0.36 mM NaH2PO4,
1 mM EGTA, supplemented with 5 mM glucose and 0.6
ADPase units/ml of apyrase, pH 6.2). Platelets were washed
and finally resuspended in buffer B (pH 7.4), which was
same as buffer A but without EGTA and apyrase. The final
cell count was adjusted to 0.8–1.2109/ml.
2.3. Platelet aggregation studies
Platelets were stirred at 37 8C in a Chronolog platelet
ionized calcium aggregometer (model 600) for 2 min prior
to addition of TRAP (20 to 80 AM) or thrombin (0.1 to 1 U/
ml). When indicated, CaCl2 (2 mM) was added 15 s before
agonist addition. In parallel samples EGTA (5 mM) was
added 90 s after agonist addition. Aggregation was
measured as the percent change in light transmission where
100% refers to the transmittance in the blank. Disaggrega-
tion at any time point was expressed as the percent decrease
in the amplitude of aggregation relative to the maximum
amplitude achieved. Platelets were pretreated at 37 8C with
PAO (2 AM) or sodium orthovanadate (7.5 mM) for 5 min
prior to addition of the agonist to inhibit tyrosine
phosphatases. In some experiments these inhibitors were
added 90 s after agonist addition. Platelets were preincu-
bated with abciximab (50 Ag/ml) for 5 min to prevent
fibrinogen binding to the integrin aIIbh3, or calpeptin (30
AM) for 30 min to inhibit calpain. Preincubation with
wortmannin (150 nM) or LY 294002 (25 AM) was done for
10 min to inhibit PI 3-kinase. In some experiments,
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addition. Wherever indicated, PMA (100 nM) was used
along with TRAP for activating the platelets. Control
platelets were incubated with DMSO at volumes same as
those of PAO, calpeptin, wortmannin, LY 294002 or PMA,
respectively; volume of DMSO did not exceed 1% of total
volume in any of the experiments. For analysis of protein
phosphorylation, platelets were transferred to one-fourth
volume of 5 sample buffer which was supplemented with
5 mM EGTA and 5 mM EDTA in order to inhibit calpain
activity during cell lysis.
2.4. Isolation of detergent lysates of platelets
The Triton X-100-insoluble fraction (cytoskeleton) was
isolated as described previously [23]. Briefly, platelets were
lysed by adding equal volumes of ice-cold 2 Triton lysis
buffer (pH 7.5) containing 2% Triton X-100, 100 mM Tris–
HCl, 10 mM EGTA, 10 mM EDTA, 2 mM sodium
orthovanadate, 21 AM leupeptin, 2 mM phenylmethylsul-
fonyl fluoride, 20 AM pepstatin A and 0.56 trypsin inhibitor
unit/ml aprotinin. After keeping on ice for 10 min, samples
were briefly vortexed and spun at 16,000g for 15 min at 4
8C in a microcentrifuge. The pellets (Triton-insoluble
cytoskeleton) were washed without resuspension in 1
Triton lysis buffer and finally solubilized in 1 sample
buffer by heating at 95 8C for 10 min.
2.5. Immunoprecipitation experiments
Immunoprecipitation was carried out as described pre-
viously [22]. Briefly, platelet suspension (0.5 ml) was
treated with equal volume of 2 lysis buffer (pH 7.4, 2%
Triton X-100, 2 mM EGTA, 2 mM EDTA, 100 mM HEPES,
150 mM NaCl, 2 mM Na3VO4, 21 AM leupeptin, 2 mM
phenylmethylsulfonyl fluoride, 20 AM pepstatin A and 0.56
trypsin inhibitor unit/ml aprotinin) on ice. The lysate was
clarified by centrifugation. The supernatant was precleared
with rabbit IgG and protein A-sepharose, and then incubated
with 5 Ag of anti-SHP-1 or 1 Ag of anti-integrin aIIbh3 for 3
h followed by protein A-sepharose for 1 h. The immuno-
precipitates were pelleted by centrifugation for 5 min at
16,000g, washed twice in 1 lysis buffer (without
protease inhibitors) and once each with high salt buffer
(100 mM HEPES, 0.5 M NaCl, pH 8) and 0.5 M HEPES
(pH 8) and finally solubilized in 30 Al of 2 sample buffer.
2.6. Immunoblotting studies
Platelet proteins were separated on 10% SDS-PAGE gels
and electrophoretically transferred to Immobilon-P PVDF
membranes (Millipore Corp., Bedford, MA) by using
NovaBlot semidry system (Amersham Biosciences) as per
manufacturer’s instructions. The membranes were blocked
with 10% bovine serum albumin in 10 mM Tris–HCl, 150
mM NaCl, pH 8.0 (TBS) containing 0.05% Tween-20 for 2h at room temperature. The blots were then incubated for 2 h
with different concentrations of primary antibodies as
follows: rabbit anti-SHP-1, 0.1 Ag/ml; rabbit anti-integrin
aIIbh3, 0.8 Ag/ml; anti-Src mAb, 0.1 Ag/ml, or anti-
phosphotyrosine (clone PY99, 0.2 Ag/ml, or clone PY20,
2 Ag/ml). Following washing, the blots were incubated for 1
h with horseradish peroxidase-labeled anti-rabbit IgG or
anti-mouse IgG as required. The antibody binding was
detected using enhanced chemiluminescence and quantified
in an Agfa Duoscan T1200 flatbed scanner using GeneTools
software (Syngene, UK). Whenever necessary, blots were
stripped of primary and secondary antibodies by incubation
for 10 min at 70 8C in the stripping buffer (TBS containing
0.05% Tween-20, 2% SDS and 1% 2-mercaptoethanol)
[24,25] and reprobed.
2.7. Presentation of data
Data are presented as meanFS.E. of at least three
individual experiments from different blood donors. Anal-
ysis of statistical significance was performed using Stu-
dent’s unpaired or paired t-test. Immunoblots shown are
representative of at least three different experiments.3. Results
3.1. TRAP-induced platelet disaggregation is regulated by
extracellular calcium, activities of phosphoinositide 3-
kinase and protein kinase C (PKC), and is independent of
calpain
TRAP (20 AM) elicited maximal aggregation of the
platelets within 2 min, followed by disaggregation (by
43.8F7.2%, n=14) upon 15-min exposure to the agonist in
presence of extracellular calcium (2 mM) (Fig. 1a, tracing
1). Addition of EGTA (5 mM) to the sample 90 s after
TRAP resulted in disaggregation by only 11.4F3.7%
(n=14) (Fig. 1a, tracing 2), which was significantly less
than that in presence of calcium (Pb0.001) as reported
earlier [26]. Addition of EGTA 5 min after agonist addition
(before the onset of disaggregation) also prevented platelet
disaggregation to similar extent (not shown). There was no
qualitative difference in the aggregation profile when the
concentration of TRAP was increased up to 80 AM and
when experiments were carried out with platelets without
aspirin pretreatment (data not shown). When platelets were
preincubated with wortmannin (150 nM) in the presence of
extracellular calcium (2 mM), the amplitude of maximal
aggregation was reduced to about 59F0.05 (n=7)% of that
in the control platelets as reported earlier [27]. This was
followed by disaggregation of platelets (by 68.5F14%,
n=5), which was significantly more compared to control
platelets (Pb0.05, paired t-test) (Fig. 1b, tracing 2). When
EGTA (5 mM) was added after 90 s of addition of TRAP in
wortmannin-preincubated platelets, there was disaggrega-
Fig. 1. Platelet disaggregation induced by TRAP is regulated by extracellular calcium, and activities of phosphoinositide 3-kinase and PKC. (a) Platelets
were aggregated with TRAP (20 AM) alone (tracings 1–2), or both TRAP (20 AM) and PMA (100 nM) (tracings 3–4), either in the presence of
calcium (2 mM, added before aggregation; tracings 1 and 3) or EGTA (5 mM, added 90 s after agonist addition; tracings 2 and 4). Aggregation was
recorded as change in light transmission in an aggregometer. (b) Platelets were aggregated with TRAP (20 AM) (tracing 1) in the presence of calcium.
In some experiments wortmannin (150 nM) was added either before (tracings 2 and 3) or 90 s after (tracings 4 and 5) addition of TRAP, either in the
presence of calcium (tracings 2 and 4) or EGTA (tracings 3 and 5) as described above. (c) Platelets were preincubated for 10 min with either DMSO
(tracings 1 and 2) or LY 294002 (25 AM) (tracings 3 and 4), and aggregated with TRAP (20 AM) either in the presence of calcium (tracings 1 and 3)
or EGTA (tracings 2 and 4) as described above. (d) Platelets were aggregated with thrombin (1 U/ml) either in the presence of calcium (tracing 1) or
EGTA (tracing 2) as described in the legend to Fig. 1a. Positions of additions of agonist and EGTA are indicated by arrows and arrowheads,
respectively.
Fig. 2. Dephosphorylation of p67 and p75 in TRAP-stimulated platelets is
regulated by extracellular calcium and is independent of calpain activity.
Washed platelets were aggregated with TRAP (20 AM) for the indicated
time periods in presence of calcium (2 mM) or EGTA (5 mM), as shown in
the figure. Wherever indicated, platelets were preincubated with either
calpeptin (30 AM) or DMSO. Cells were lysed and immunoblotted against
phosphotyrosine.
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EGTA-treated control platelets (Fig. 1b, tracing 3). As
wortmannin preincubation inhibited aggregation, we next
added wortmannin (150 nM) after 90 s of agonist addition in
the presence of extracellular calcium (2 mM), and observed
platelets to disaggregate earlier compared to the control
platelets; however, at the end of 15 min the % disaggrega-
tion was same as that in the wortmannin-pretreated platelets
(Fig. 1b, tracing 4). Addition of both EGTA and wortman-
nin 90 s after agonist addition prevented disaggregation
similar to EGTA-treated control platelets (Fig. 1b, tracing
5). Essentially similar observations were made when
platelets were treated with another pharmacologically
distinct inhibitor of PI 3-kinase, LY 294002 (25 AM) (Fig.
1c, tracings 3 and 4).
Co-stimulation of platelets with TRAP and PMA (PKC
activator, 100 nM), either in the presence or absence of
extracellular calcium, prevented disaggregation of cells at
15 min (Fig. 1a, tracings 3 and 4, respectively). As TRAP-
induced disaggregation of the platelets appeared to be a
Fig. 3. Dephosphorylation of p67 and p75 in thrombin-aggregated platelets is prevented by inhibitors of tyrosine phosphatases. Washed platelets were
aggregated in the presence of thrombin (1 U/ml) for varying time points in the presence of calcium or EGTA as indicated. PAO was added 5 min before agonist
addition (panel 1) while sodium orthovanadate was added 90 s after the agonist (panel 2). Cells were lysed and immunoblotted against phosphotyrosine.
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implicated in the calcium signaling pathway, platelets were
next preincubated with calpeptin at the concentration
sufficient to inhibit calpain (30 AM) [28] and aggregated
with TRAP in the presence of extracellular calcium. There
was no significant difference in the extent of disaggregation
at 15 min from the control platelets although the amplitude
of maximal aggregation was reduced to about 54% (data not
shown). As calpain activity is up-regulated in the aggregated
platelets and contributes to platelet responses like aggrega-
tion, secretion and spreading [29], this could explain the
observed decrease in the amplitude of platelet aggregation in
presence calpain inhibitors.
In contrast to TRAP, there was no decline in the
amplitude of aggregation when the cells were stimulated
with thrombin (1 U/ml) for 15 min irrespective of the
presence of calcium in the medium (Fig. 1d). Lowering the
concentration of thrombin up to 0.1 U/ml also did not elicit
the disaggregation response following 15-min stimulation in
the presence of calcium. Further lowering the thrombin
concentration induced only shape change without any
apparent macroaggregation, consistent with our earlier
findings [22]. When platelets were preincubated with either
calpeptin (for 30 min) or wortmannin (for 10 min) prior toFig. 4. Association of phosphorylated p67 and p75 with actin-based cytoskeleton
with either TRAP (20 AM) (panel 1) or thrombin (1 U/ml) (panel 2) for varying tim
cytoskeletal fractions were isolated and subjected to SDS-PAGE, followed by imthe addition of thrombin, or when PMA and the agonist
were added together, there was no change in the nature of
aggregation at 15 min compared to the control platelets
(data not shown). Five-minute preincubation with abcix-
imab (50 Ag/ml), the antibody directed against the platelet
surface integrin aIIbh3, resulted in almost complete inhib-
ition of platelet aggregation induced by either agonists (data
not shown).
3.2. TRAP-induced platelet disaggregation in the presence
of extracellular calcium is associated with tyrosine dephos-
phorylation of selective proteins, phosphorylation of SHP-1
and extensive cytoskeletal reorganization
In order to understand the signaling events underlying
prolonged stimulation of PAR-1 receptors in the platelets,
we studied the extent of tyrosine phosphorylation of platelet
proteins under similar conditions. Two major proteins of
relative mobilities 67 and 75 kDa were found to be
significantly less phosphorylated on tyrosine in Ca2+-
pretreated platelets as compared to the EGTA-treated
platelets following stimulation with TRAP for 15 min
(Fig. 2, lanes 2 and 3). The possibility of Ca2+-mediated
proteolysis in cell lysates was ruled out by including EDTAin TRAP/thrombin aggregated platelets. Washed platelets were aggregated
e periods in the presence of calcium or EGTA as indicated. Triton-insoluble
munoblotting against phosphotyrosine.
Fig. 6. Dephosphorylation of p67 and p75 in the TRAP-aggregated platelets
is independent of PKC. Washed platelets were aggregated with either TRAP
alone or TRAP along with PMA under different conditions as indicated.
Cells were lysed and immunoblotted against phosphotyrosine.
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Loading of equal amount of proteins in each lane was
confirmed by quantification of actin present. Essentially
similar observations were made in the platelets which were
not pretreated with aspirin (not shown). Tyrosine dephos-
phorylation of the above proteins was also observed in
thrombin (1 U/ml)-aggregated platelets following prolonged
stimulation for 15 min (Fig. 3). The phosphotyrosine
content of the 67-kDa protein after 15 min of stimulation
was 1.7F0.1 (n=8)- and 1.7F0.2 (n=5)-fold higher in
EGTA treated platelets than in the presence of calcium,
using either TRAP or thrombin, respectively, as the
agonists. In order to exclude the role of calpain, we
preincubated platelets with calpeptin (30 AM), an inhibitor
of calpain. Calpeptin, at this concentration, effectively
blocked proteolysis of actin-binding protein in the iono-
phore A23187-treated platelets in the presence of extrac-
ellular calcium [28]. However, calpeptin treatment did not
prevent selective dephosphorylation of p67 and p75 in either
TRAP- or thrombin-aggregated platelets (Fig. 2, lane 5, and
data not shown), thus ruling out calpain-mediated proteol-
ysis of these proteins. In order to find out whether
dephosphorylation was due to the activity of protein
tyrosine phosphatases or inhibition of protein tyrosine
kinases, we preincubated platelets with PAO (2 AM)
[30,31] or sodium orthovanadate (7.5 mM) [32], both
inhibitors of protein tyrosine phosphatases, and stimulated
the cells in the presence of calcium. PAO induced minor
enhancements (by about 25%) in the phosphotyrosine
content in the unstimulated platelets, as well as in the
platelets stimulated for 2 min (Fig. 3, panel 1). However,
following 15-min stimulation of platelets, the calcium-
sensitive dephosphorylation of p67 was recovered by about
70% in the PAO-pretreated platelets (Fig. 3, panel 1),
suggestive of the major role of tyrosine phosphatase/s in this
process. As tyrosine phosphatases are up-regulated in the
post-aggregation phase [22], we next added either PAO orFig. 5. Dephosphorylation of p67 and p75 in the TRAP-aggregated platelets
is independent of PI 3-kinase activity. Washed platelets were aggregated
with TRAP (20 AM) in the presence of either calcium or EGTA for the time
indicated. Wortmannin (150 nM) was added either before (dwort (pre)T) or
90 s after (dwort (post)T) addition of TRAP. Cells were lysed and
immunoblotted against phosphotyrosine.orthovanadate after 90 s of agonist activation. PAO was
again found to recover about 59% of dephosphorylation (not
shown), while orthovanadate completely prevented dephos-
phorylation of p67 (Fig. 3, panel 2). However, a recent
report suggesting modification of platelet surface vicinal
dithiols and aggregation by PAO [33] cannot be ruled out
under these experimental conditions. Thus, we surmise that
calpain-insensitive tyrosine phosphatase/s were activated in
the later phase of aggregation in a process regulated by
extracellular calcium.
Aggregation of platelets for 2 min with or without
calcium resulted in the association of multiple tyrosine
phosphorylated proteins (of relative mobilities 75, 67 and
62–50 kDa) with the actin-based cytoskeleton (Fig. 4) [34].
Following prolonged stimulation with TRAP, cytoskeletal
p67 was about 65% less phosphorylated in the calcium-
treated platelets, as compared to only 30% less phosphor-
ylation in the platelets treated with EGTA (Fig. 4, panel 1),
thus linking tyrosine phosphatase activity with the actin-
based cytoskeleton. However, this could also be attributed
to differences in the amounts of proteins associating with the
cytoskeleton under varying experimental conditions. SimilarFig. 7. SHP-1 is tyrosine phosphorylated in TRAP-aggregated platelets in a
calcium-dependent manner. Platelets were aggregated with TRAP (20 AM)
for the time indicated. Platelet lysates were precleared and incubated with
either anti-SHP-1 antibody (lanes 2–5) or rabbit IgG (lane 1). Immunopre-
cipitates were separated by SDS-PAGE and immunoblotted using anti-
bodies against phosphotyrosine (panel A) or SHP-1 (panel B). Lanes 1 and
2 represent unstimulated platelets.
Fig. 8. Integrin aIIbh3, but not SHP-1, dissociates from the cytoskeleton of
TRAP-aggregated platelets in a calcium-dependent manner. Platelets were
aggregated with TRAP (20 AM) for the time indicated. Cytoskeletal
fractions (CSK) were isolated after lysis with Triton X-100 and probed
using specific antibodies against integrin aIIbh3 or SHP-1. WP, washed
platelet lysates.
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platelets (Fig. 4, panel 2).
Wortmannin is known to inhibit PI 3-kinase activity at
low concentrations [27]. As our observations strongly
favored TRAP-mediated disaggregation to be a PI 3-kinase
regulated process (Fig. 1), which was consistent with earlier
reports [27, 35], we studied the phosphotyrosine content of
p67 in wortmannin-preincubated platelets. As in the control
platelets, p67 was found to be dephosphorylated in the
presence of Ca2+ in wortmannin (150 nM)-pretreated
platelets (Fig. 5). Hence, the tyrosine phosphatase activity
appeared to be independent of PI 3-kinase. As shown
earlier, wortmannin preincubation also inhibited the ampli-
tude of maximal aggregation (Fig. 1, tracing 3). Addition of
wortmannin to platelets 90 s after agonist addition (after
maximal aggregation) caused early disaggregation but theFig. 9. Dephosphorylation of p67 and p75 in TRAP-aggregated platelets is depende
c) as well as a patient of Glanzmann’s thrombasthenia (panels a and b) were pre
stimulated with TRAP (20 AM) for different time periods. Cells were lysed. Platel
(panel a) or phosphotyrosine (panels b and c).phosphotyrosine contents of p67 were essentially similar to
those observed in the wortmannin-preincubated platelets
(Fig. 5). Similar observations were also made using another
pharmacologically independent inhibitor of PI 3-kinase, LY
294002, at concentrations sufficient to inhibit PI 3-kinase
(not shown).
As TRAP-induced disaggregation was modulated by
PKC (Fig. 1, tracing 7), we checked the phosphotyrosine
content of p67 under similar experimental conditions.
Although disaggregation was inhibited with addition of
PMA along with TRAP, dephosphorylation of p67 was not
prevented (Fig. 6). Addition of EGTA, however, prevented
dephosphorylation of this protein (Fig. 6). Thus, tyrosine
dephosphorylation of p67 in the presence of extracellular
calcium was not associated exclusively with disaggregation
(disaggregation was absent in the platelets stimulated with
TRAP plus PMA, or with thrombin) and involved tyrosine
phosphatase/s acting independent of calpain, PI 3-kinase or
PKC.
P67 co-migrated with the tyrosine phosphatase SHP-1,
whereas Syk and SHP-2 had lower electrophoretic mobility
(not shown). To find out whether p67 identified with SHP-1,
the latter was immunoprecipitated from platelet lysates
following 15-min stimulation with TRAP in the presence of
either calcium or EGTA. SHP-1 was found to be phos-
phorylated on tyrosine in the Ca2+-pretreated platelets,
whereas no phosphorylation of SHP-1 was observed in the
EGTA (5 mM)-treated cells (Fig. 7). This finding ruled out
the possibility that p67 could be identical with SHP-1. In
order to implicate SHP-1 activity with tyrosine dephosphor-nt on aIIbh3 engagement. Platelets obtained from healthy individuals (panel
treated with abciximab (50 Ag/ml) for 5 min as indicated. The cells were
et proteins were subjected to SDS-PAGE and immunoblotted against aIIbh3
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distribution of the phosphatase was studied under similar
experimental conditions. Consistent with previous reports
[36], SHP-1 associated with the cytoskeleton of the
aggregated platelets, with several other signaling proteins
including integrin aIIbh3 and Src.
However, following prolonged stimulation of the
platelets with TRAP in the presence of Ca2+, there was
complete dissociation of integrin aIIbh3 (Fig. 8) and Src
(not shown) from the cytoskeleton [26] whereas the
cytoskeletal content of SHP-1 remained intact (Fig. 8).
As phosphorylation of cytoskeletal p67 was reduced
following prolonged platelet stimulation in presence of
calcium (Fig. 4), this suggested a possible role of SHP-1 in
the cytoskeletal dephosphorylation events.
Ligation of platelet PAR-1 with agonists like TRAP or
thrombin leads to activation of integrin aIIbh3, resulting in
platelet aggregation and ensuing outside-in signaling. In
order to find out the role of integrin aIIbh3 with respect to
the observed dephosphorylation of p67 and p75, platelets
were pretreated with abciximab, a monoclonal antibody
directed against aIIbh3, which inhibited platelet aggregation.
In another study, aggregation in TRAP-stimulated platelets
was prevented by incubating the cells in the absence of
stirring. Aggregation was also completely absent in TRAP-
treated platelets obtained from a case of type II Glanzmann’s
thrombasthenia, which contains less than 12% of integrin
aIIbh3 in comparison to the control (Fig. 9a). In the above
instances, stimulation of PAR-1 for 15 min in the presence
of extracellular calcium did not elicit any significant
difference in the phosphotyrosine contents of p67 and p75
(Fig. 9b and c), thus implicating the requirement of
functional aIIbh3 in the observed phosphorylation and
dephosphorylation events.4. Discussion
Signaling induced by platelet PAR-1 ligation leads
to binding of polyvalent fibrinogen to the surface inte-
grin aIIbh3 and platelet aggregation. Integrin engagement
evokes outside-in signaling, which results in morphological
changes like clot retraction, microvesicle release and re-
versal of aggregation. Although the mechanisms underlying
aggregation have been well studied, signaling pathways
associated with the post-aggregation events have not invited
serious attention. In an in vivo setting, platelets continue to
be exposed to the agonists long after the aggregation is
initiated and the ensuing disaggregation of the platelets
elicited by a strong agonist (TRAP) or the phase of
reversibility induced by weak agonists (ADP or epinephr-
ine) could facilitate clot dissolution; hence, understanding
the signaling processes has therapeutic relevance. Disag-
gregation of the platelets is attributed to a decrease in the
affinity of aIIbh3 towards fibrinogen, rather than a decrease
in the surface availability of the integrin [22], and isassociated with a parallel alteration in outside-in signaling
mediated through the ICY motif of h3 subunit [37]. In this
paper, we further demonstrate that TRAP-induced disag-
gregation of the platelets is a function of extracellular
calcium. Chelation of Ca2+ with EGTA precluded subse-
quent destabilization of the aggregates in TRAP-stimulated
platelets. Although EGTA would prevent calcium entry/
uptake by reducing extracellular calcium level, it can also
evoke novel signaling pathways through subunit dissocia-
tion of the aIIbh3 integrin [38]. The latter possibility was
unlikely under our experimental conditions, as EGTA was
found to sustain aggregation of the platelets when added 90
s after agonist stimulation (Fig. 1a). However, we do not
have evidence to rule out partial dissociation of the integrins
under these conditions.
Disaggregation was found to be independent of the
activity of the calcium-dependent thiol protease, calpain.
Activity of PI 3-kinase is known to stabilize platelet
aggregates [27]. Consistent with this report, platelet
aggregation was found to be destabilized by inhibition of
PI 3-kinase in the presence of calcium, whereas chelation
of calcium under similar conditions led to stabilization of
the aggregates and reduction in the extent of disaggrega-
tion. Thus, the site of action of calcium or EGTA could be
downstream of PI 3-kinase. Activation of PKC by phorbol
ester also prevented disaggregation of the TRAP-stimu-
lated platelets. Taken together, these data suggested that
platelet disaggregation was regulated by extracellular
calcium, PKC and PI 3-kinase, and was independent of
calpain activity. Thrombin, another PAR-1 agonist with
proteolytic activity, was unable to induce calcium-sensitive
disaggregation of the platelets at concentrations ranging
from 1.0 to 0.1 U/ml. As thrombin, at lower concentration,
is known to elicit platelet activation through PAR-1, lack
of platelet disaggregation was not attributable to PAR-4
ligation. Thus, the differential response of platelets to
thrombin and TRAP could be attributed to the additional
pathways stimulated by thrombin through Gp Ib [39], apart
from PAR-1 ligation.
Tyrosine phosphorylation of proteins is a dynamic
process regulated by the coordinated activities of protein
tyrosine kinases and phosphatases. Platelet activation by
PAR-1 agonists leads to waves of rapid tyrosine
phosphorylation of multiple proteins [40]. Concomitantly,
protein tyrosine phosphatases are also activated which
dephosphorylate selective substrates [19,21,41,42]. We
have recently shown that kinase activity is the predom-
inant factor determining the level of phosphorylation in
the early phase of aggregation, while protein tyrosine
phosphatases regulate the subsequent dephosphorylation
of platelet proteins following prolonged stimulation [22].
In the present study, sustained exposure of platelet PAR-1
to agonists in the presence of extracellular Ca2+ is shown
to be associated with dephosphorylation of selective
substrates such as p67 and p75. Chelation of extracellular
calcium prevented dephosphorylation of both peptides.
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phosphatases implicated the phosphatase activity in the
observed dephosphorylation events during the later part
of aggregation. Dephosphorylation was, however, inde-
pendent of the Ca2+-dependent thiol protease calpain.
Inhibition of PI 3-kinase by two pharmacologically
distinct inhibitors also caused dephosphorylation of p67,
which was completely abrogated by chelation of extrac-
ellular calcium. Neither the identity of p67 nor of the
tyrosine phosphatase(s) responsible for its dephosphor-
ylation was known. Although SHP-1, an abundant
tyrosine phosphatase in platelets, co-migrated with the
p67 protein, its identity with p67 was ruled out from
immunoprecipitation studies. SHP-1 itself was phosphory-
lated on tyrosine following 15-min stimulation with
TRAP when the platelets were incubated with Ca2+ but
not with EGTA (Fig. 7). As tyrosine phosphorylation of
SHP-1 induces its enzymatic activity [43], this could
account for the observed dephosphorylation of proteins in
the Ca2+-treated platelets.
The association of the major platelet integrin aIIbh3 and
the signaling molecules like focal adhesion kinase, Src,
CDC42Hs and Rap1B with the cytoskeleton of aggregated
platelets is a reversible process regulated by Ca2+ [26].
Chelation of extracellular Ca2+ prevented their dissociation
from the cytoskeleton. Interestingly, and in contrast to
these regulatory proteins, cytoskeletal content of SHP-1
was not reduced upon prolonged stimulation of platelets in
presence of extracellular Ca2+. As both SHP-1 and the
partially dephosphorylated p67 were localized in the actin-
based cytoskeleton of the TRAP-disaggregated platelets,
the observed dephosphorylation could be attributed to the
activity of SHP-1. Despite its cytoskeletal association [36],
PTP1B would be an unlikely candidate, as it is cleaved by
calpain in the aggregated platelets [44] and involvement of
calpain activity has been ruled out in the present study.
Incubation with thrombin was not associated with
cytoskeletal destabilization or disaggregation of platelets
following prolonged stimulation. Neither the amount of
F-actin nor the cytoskeletal contents of Src, SHP-1 and
integrin aIIbh3 changed significantly when thrombin-
induced aggregation was continued in the presence of
Ca2+ (not shown). However, tyrosine dephosphorylation
of the selective substrates including p67 occurred in the
absence of platelet disaggregation and cytoskeletal desta-
bilization in the thrombin-stimulated platelets. Dephos-
phorylation of p67 was also observed in platelets
stimulated jointly by PMA and TRAP where platelets
were not found to disaggregate. Hence, dephosphorylation
of the specific substrates on tyrosine occurred independ-
ent of platelet disaggregation. It can be surmised that
dephosphorylation in the presence of extracellular calcium
is a consequence of outside-in signaling evoked by
integrin ligation, irrespective of the nature of the agonist
(please see below). Concomitantly, the aggregates get
destabilized following prolonged incubation with TRAP,and not by thrombin, possibly due to additional signaling
inputs elicited by the latter.
In a recent study, Osdoit and Rosa [41] have linked clot
retraction to tyrosine dephosphorylation of platelet proteins
of 60- and 85-kD sizes. Formation of clot is ruled out under
our experimental conditions as no extraneous fibrinogen is
added to the platelet suspension and TRAP, unlike
thrombin, has no enzymatic activity for cleavage of
fibrinogen. Microvesicle release has also been reported to
be associated with protein tyrosine dephosphorylation in the
platelets [19]. Thus, above observations and the results from
the present study are consistent with the notion that tyrosine
dephosphorylation is a common underlying factor during
the post-aggregation events in platelets.
The major platelet integrin aIIbh3 has been implicated
in the regulation of tyrosine phosphorylation and dephos-
phorylation in activated platelets [36,45]. To investigate
the role of integrin occupancy on tyrosine dephosphor-
ylation of p67 and p75, we stimulated the thrombasthenic
platelets or normal platelets preincubated with abciximab,
an aIIbh3 blocking antibody, with TRAP. In both cases,
there was no change in the phosphotyrosine contents of
p67 and p75, as against the control, when stimulation
was continued for up to 15 min. This suggests that aIIbh3
engagement regulates the tyrosine dephosphorylation
events in the activated platelets, which is consistent with
the earlier observations by Osdoit and Rosa [41]. Integrin
ligation could lead to activation of a putative tyrosine
phosphatase, resulting in observed dephosphorylation of
p67 and p75. The h3 subunit of the integrin is also
known to be tyrosine phosphorylated in the ICY motif in
aggregated platelets [46]. Constitutive substitution of the
tyrosine with phenylalanine was shown to prevent
optimal platelet aggregation and clot retraction, whereas
it augments disaggregation [37]. We, however, were
unable to detect tyrosine phosphorylation of h3 nor its
association with other proteins by immunoprecipitation
using a polyclonal antibody against aIIbh3 (data not
shown).
In summary, our data suggested that sustained stimula-
tion of platelet PAR-1 with either TRAP or thrombin is
associated with tyrosine dephosphorylation of a novel p67
peptide in a process regulated by extracellular calcium.
SHP-1 appears to be the likely candidate for the phosphatase
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